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DOI 10.1186/s12916-015-0400-xRESEARCH ARTICLE Open AccessAge-related frailty and its association with
biological markers of ageing
Arnold Mitnitski1, Joanna Collerton2, Carmen Martin-Ruiz3, Carol Jagger2, Thomas von Zglinicki4,
Kenneth Rockwood5 and Thomas B. L. Kirkwood4*Abstract
Background: The relationship between age-related frailty and the underlying processes that drive changes in
health is currently unclear. Considered individually, most blood biomarkers show only weak relationships with
frailty and ageing. Here, we examined whether a biomarker-based frailty index (FI-B) allowed examination of their
collective effect in predicting mortality compared with individual biomarkers, a clinical deficits frailty index (FI-CD), and
the Fried frailty phenotype.
Methods: We analyzed baseline data and up to 7-year mortality in the Newcastle 85+ Study (n = 845; mean age 85.5).
The FI-B combined 40 biomarkers of cellular ageing, inflammation, haematology, and immunosenescence. The
Kaplan-Meier estimator was used to stratify participants into FI-B risk strata. Stability of the risk estimates for the
FI-B was assessed using iterative, random subsampling of the 40 FI-B items. Predictive validity was tested using
Cox proportional hazards analysis and discriminative ability by the area under receiver operating characteristic
(ROC) curves.
Results: The mean FI-B was 0.35 (SD, 0.08), higher than the mean FI-CD (0.22; SD, 0.12); no participant had an FI-B
score <0.12. Higher values of each FI were associated with higher mortality risk. In a sex-adjusted model, each
one percent increase in the FI-B increased the hazard ratio by 5.4 % (HR, 1.05; CI, 1.04–1.06). The FI-B was more
powerful for mortality prediction than any individual biomarker and was robust to biomarker substitution. The
ROC analysis showed moderate discriminative ability for 7-year mortality (AUC for FI-CD = 0.71 and AUC for FI-B = 0.66).
No individual biomarker’s AUC exceeded 0.61. The AUC for combined FI-CD/FI-B was 0.75.
Conclusions: Many biological processes are implicated in ageing. The systemic effects of these processes can be
elucidated using the frailty index approach, which showed here that subclinical deficits increased the risk of death. In
the future, blood biomarkers may indicate the nature of the underlying causal deficits leading to age-related frailty,
thereby helping to expose targets for early preventative interventions.
Keywords: Ageing, Biomarkers, Cellular ageing, Deficit accumulation, Frailty, Frailty index, Frailty phenotype,
Immunosenescence, Inflammation, Newcastle 85+ studyBackground
The ageing process is characterized by declining func-
tional capacity and increasing vulnerability to disease,
disability, and death. This is driven by the gradual, life-
long accumulation of molecular and cellular defects [1].
Individuals of a given chronological age vary, however,
in how far these processes have advanced. Some enter a* Correspondence: tom.kirkwood@ncl.ac.uk
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creativecommons.org/publicdomain/zero/1.0/state of increased risk, compared with others of the same
age, known as frailty [2]. Connecting the clinical state of
age-related frailty with underlying biological age, as mea-
sured by biomarkers, has long been an elusive goal.
Frailty can be evaluated, and health status quantified,
by the number of health deficits that individuals accumu-
late. Specifically, the frailty index (FI) is the ratio of the
deficits present in a person to the total number of poten-
tial deficits evaluated [3]. The FI has been used in many
epidemiological and clinical studies to grade the degree
of risk of several adverse outcomes, including mortality,article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ening health, and loss of independence [4–9], as well as
conditions such as cognitive impairment [10], heart dis-
ease [11], osteoporosis [12], intellectual disability [13], and
systemic sclerosis [14]. In most studies, the FIs have been
made up of clinically-assessed health deficits [9].
In a comprehensive study of biomarkers of cellular
ageing, inflammation, and immunosenescence, Collerton
et al. [15] identified several biomarkers associated with
frailty (assessed both by the FI and the Fried frailty
phenotype [16]), where each biomarker was considered
separately from the others. Although such an analysis
can identify important specific effects, it is known that
complex interactions between ageing mechanisms and
biomarkers are likely [17, 18]. Within the present work,
we significantly extend our previous analyses by com-
bining different biomarker measures into a FI, which
may make it possible to discern a systemic effect that
might be masked when the variables are used in isola-
tion [19].
In principle, a FI of clinical health deficits should reflect
the accumulation of damage at the level of the organism
due to impairment of macroscopic and microscopic repair
processes [20]. We were therefore interested to know
whether combining biomarkers of deficits at the levels
of tissue (anaemia, inflammatory markers) and cells
(e.g., DNA damage, telomere length) would add to the
ability of a FI based on clinical deficits (Clinical Deficits
Frailty Index; FI-CD) to predict adverse outcomes.
Our objectives were 1) to develop a FI based on bio-
markers (Biomarker Frailty Index; FI-B); 2) to investigate
the robustness of the FI-B in relation to the specific bio-
markers included; and 3) to test its predictive value in
relation to death, compared to other frailty measures
(FI-CD, Fried phenotype) and individual biomarkers.Methods
Participants
As detailed elsewhere, the Newcastle 85+ Study is a
population-based cohort study of people born in 1921,
aged 85 at recruitment, living in Newcastle upon Tyne
and North Tyneside (North East England); the cohort
was socio-demographically representative of the local
population and of England and Wales [21–23]. The re-
search complied with the requirements of the Declaration
of Helsinki. Ethical approval was obtained from the New-
castle and North Tyneside 1 Research Ethics Committee
(reference number 06/Q0905/2). Written informed con-
sent was obtained from participants and where people
lacked capacity to consent, for example because of demen-
tia, a formal written opinion was sought from a relative
or carer. Participants could decline any or all elements
of the protocol.Data sources
A multidimensional health assessment was carried out in
the participant’s usual residence by a research nurse. Data
on pre-existing diseases and prescribed medications were
obtained from general practice medical records.
Blood-based biomarkers
Biomarkers were measured from a blood sample drawn
between 7 am and 10:30 am following an 8 h overnight
fast and delivered to the laboratory for initial processing
within 1 hour of draw. The 40 biomarkers investigated
included inflammatory, haematological, immunological,
cell senescence, genetic, and epigenetic markers, and were
analyzed according to either previously reported methods
[24] or those described in Additional file 1: Material and
Methods.
Recoding (dichotomizing) biomarkers as deficits
Each biomarker was measured on a continuous scale and
values were dichotomized into ‘deficit’ versus ‘no deficit’
using empirical cut points, chosen to achieve the best
separation of survival curves between people with and
without the deficit by minimizing the P value of the log
rank test (Table 1, Additional file 1: Figure S1).
Frailty measures
The FI-B was constructed by combining results for up to
40 biomarkers. For each dichotomized biomarker, a
standard procedure was followed such that zero equals
the absence of the deficit and 1 equals its presence.
For any individual participant, the number of deficits
was summed and divided by the number of potential
deficits evaluated. In consequence, an individual with
no deficits would have an FI = 0, and someone with
every deficit present would have an FI = 1, although
previous work has shown that empirically the ceiling
for FIs is generally observed at a score of 0.7 or less
[4]. The FIs were calculated only if more than 80 % of
the component variables were available for a given in-
dividual. The FI-B was calculated in 777 participants.
For illustrative purposes, we considered four FI-B strata
(low, low-to-intermediate, intermediate-to-high, and high-
est risk of mortality) defined using empirical cut-points
of 0.25, 0.38, and 0.50, respectively, based on maximum
separation of mortality curves.
The FI-CD had been calculated earlier from 40 clinical
variables in 811 participants [15]. In the same previous
work, the Fried frailty phenotype had also been derived in
552 participants (the chief reason why the sample for the
Fried frailty phenotype was substantially lower that for the
FIs was the exclusion, as per the stipulated Fried method-
ology, of participants with conditions which might cause
them to score as frail as a result of that condition alone;
in brief, reasons for exclusion were stroke, Parkinson’s
Table 1 Individual biomarkers used to compose the frailty indices (FI-B). The cut off points were defined to achieve the best
separation of survival curves between people with and without the deficit and minimizing the P value of the log rank test
Biomarker Cut off
point
Direction
of risk
Number of participants P value**
At lower risk At higher risk
Inflammation*
Cytomegalovirus serology (IgG) Positive 108 641 0.327
High sensitivity C-reactive protein (mg/L) >25 High 737 37 <0.001
IL-6, basal (pg/mL) >15 High 27 676 0.399
IL-6, post-stimulation (pg/mL) >1100 High 176 527 0.92
TNF-alpha, basal (pg/mL) <95 Low 55 637 0.646
TNF-alpha, post-stimulation (pg/mL) >80 High 60 643 0.116
Leptin (ng/mL) <40 Low 214 495 0.023
Adiponectin (μg/mL) >20 High 657 83 0.012
Homocysteine (μmol/L) >30 High 422 35 0.006
Albumin (g/L) <40 Low 365 397 <0.001
Haematological
Haemoglobin (g/dL) <11 Low 676 76 <0.001
Platelets (×109/L) <170 Low 675 73 0.003
White blood cells (×109/L) >7 High 470 274 0.035
Neutrophils (×109/L) >7 High 715 29 0.007
Lymphocytes (×109/L) <1.5 Low 530 214 0.028
Monocytes (×109/L) >0.75 High 639 105 0.14
Basophils (×109/L) <0.06 Low 156 588 0.156
Eosinophils (×109/L) >0.5 High 688 56 0.15
Immunosenescence
CD4 T cells (% T cells) <44 Low 345 367 0.029
CD8 T cells (% T cells) >35 High 579 128 0.015
CD8 TEMRA T cells (% CD8 T cells) >0.6 High 672 36 0.014
Senescent Memory CD4 T cells (% Memory CD4 T cells) >70 High 618 93 0.079
Memory CD4 T cells (% CD4 T cells) >35 High 672 43 0.057
CD4/CD8 T cell ratio <0.6 Low 662 31 0.005
Memory/naïve CD4 T cell ratio >3.3 High 692 20 0.034
Memory/naïve CD8 T cell ratio >15 High 677 20 0.352
Memory/naïve B cell ratio >2.5 High 652 36 0.026
Cellular ageing/Oxidative stress
Telomere length (bp) <3000 Low 634 66 0.118
DNA repair (%) <20 Low 589 156 0.078
DNA damage/DNA repair ratio >6.5 High 688 44 0.063
TGF beta, transforming growth factor beta (ng/mL) <20 Low 102 644 0.003
IGFBP1, insulin-like growth factor-binding protein 1 (ng/mL) >150 High 574 162 0.001
IGFBP3, insulin-like growth factor-binding protein 3 (ng/mL) <800 Low 92 652 0.357
iPF2alpha-III (LC/MS/MS) (ng/mL) <4.5 Low 85 629 0.053
iPF2alpha-VI (LC/MS/MS) (ng/mL) <4 Low 423 291 0.1
iPF2alpha-III (AutoDELFIA) (ng/mL) <0.6 Low 512 103 0.258
Genetic/Epigenetic
Mitochondrial DNA haplogroup X, I, heteroplasmic 675 30 0.031
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Table 1 Individual biomarkers used to compose the frailty indices (FI-B). The cut off points were defined to achieve the best
separation of survival curves between people with and without the deficit and minimizing the P value of the log rank test
(Continued)
APOE genotype E4 454 167 0.024
CPG island DNA methylation (%) >7 High 28 451 0.67
Line1 DNA methylation, surrogate for genome-wide DNA methylation (%) >80 High 73 197 0.63
*The recorded cytokine levels may be perceived as higher than usual. Because we wanted to measure basal and post-stimulated cytokines, we measured cytokines in
non-coagulated LiHe blood, using blood supernatants, not serum. Furthermore, we used an electrochemiluminescent method (MSD technology) that in our hands is
much more sensitive than standard ELISA assays. Both factors are likely to explain our observed cytokine levels
**Statistically significant P-values (≤0.05) are shown in bold
Mitnitski et al. BMC Medicine  (2015) 13:161 Page 4 of 9disease, mini-mental state examination score of less than
18, or taking drugs for dementia, Parkinson’s disease, or
depression).
Data analysis
Kaplan-Meier survival and Cox proportional hazard models
were used to estimate the probability of survival, in which
FI values were converted to 0–100 integers by rounding
them after multiplying them by 100, giving equal percent
increments for modelling. To evaluate the robustness
of the separation of the FI-B strata, we randomly selected
up to 30 out of 40 biomarkers/deficits and repeated the
Kaplan-Meier survival analysis 1,000 times. We also com-
pared different versions of the FI-B to address whether ef-
fects were cumulative or driven by just a few biomarkers.
The hazard ratios (HR) of the FIs (FI-B and FI-CD)
were adjusted for sex, and considered separately and to-
gether. Receiver operating characteristic (ROC) analysis
was used to assess the discriminative ability of the FIs,
separately and in combination, as well as the Fried frailty
phenotype and individual biomarkers, in relation toFig. 1 Histograms of the a Clinical Deficit Frailty Index (FI-CD) and b Biomarker
with the parameters of shape and scale 18.77 and 0.02 for FI-CD and 3.24 and 0mortality. The confidence intervals for the ROC were
calculated using bootstrapping, with 1,000 replications.
Data analysis was conducted using SPSS Version 21 (IBM
SPSS.) The statistical significance level was set at P <0.05.Results
Biomarker-based frailty index (FI-B)
The mean age of the sample of 777 people in whom the
FI-B could be calculated was 85.5 years (SD, 0.4). Most
were women (60.9 %). The FI-B and FI-CD samples did
not differ significantly in sex, years of education, percent
smokers, body mass index, or cognition (Additional file
1: Table S2).
The FI-B showed a slightly skewed distribution, fitted
by the gamma density function with shape and scale pa-
rameters of 18.77 and 0.02, respectively (Fig. 1, Panel b).
The 5th centile of the FI-B was 0.24, and the 95th and
99th centiles were 0.48 and 0.60, respectively. The histo-
gram of the FI-CD was more skewed with a longer right tail
(Fig. 1, Panel a); the gamma fit shape and scale parametersFrailty Index (FI-B), and the best fit gamma density functions (solid lines)
.07 for FI-B, respectively
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FI-CD was 0.06, and the 95th and 99th centiles were 0.46
and 0.59, respectively. The mean FI-B was 0.35 (SD, 0.08),
higher than the mean FI-CD of 0.22 (SD, 0.12). Individual
values of the FI-B were weakly correlated with the FI-CD
(r = 0.16, P <0.001). On average, the clinically fittest people
(those with 0 or 1 clinical deficits, i.e., FI-CD = 0 or 0.02)
had an average FI-B value of 0.33 (CI, 0.32–0.34), com-
pared with an average FI-B value of 0.39 (CI, 0.36–0.41)
for the clinically frailest people (FI-CD >0.5).
Of the 40 biomarkers used to compose the FI-B, 21
showed significant differences (P <0.05) in mortality
between people with and without each deficit (Table 1). Of
those 21 biomarkers, nine demonstrated a high separation
of survival curves, with log rank P <0.001.
The FI-B was strongly associated with 7-year mortality.
In the Cox proportional hazards model adjusted for sex
(female sex is protective; HR, 0.73; CI, 0.60–0.88), each
one percent increase in FI-B was associated with 5.4 %
increase in the hazards ratio (HR, 1.05; CI, 1.04–1.07).
Likewise, the Kaplan-Meier survival curves showed the ef-
fect of increasing frailty across the four FI-B strata (Fig. 2a).
This pattern was robust: random sub-samplings of 30
biomarkers out of the 40 available also showed good
separation between the four strata, with only little overlap
between neighbouring groups (Fig. 2b). With decreasing
numbers of biomarkers included, the overlap between
the groups greatly increased (Additional file 1: Figure
S2). Notably, amongst those who clinically were not
frail (FI-CD scores in the lowest quartile) having an FI-BFig. 2 a Kaplan-Meier survival curves of the FI-B for the four risk strata de
0.25–0.38 (low-intermediate risk, n = 217), green 0.38–0.49 (intermediate-h
survival curves of the FI-B calculated from 30 biomarkers randomly chose
same cut points as in A. The sampling was repeated 300 timeshigher than median (0.33) was associated with much
higher mortality (Fig. 3).
Comparing different versions of the FI-B
We investigated three additional versions of the FI-B.
The first (FI-B-9) was calculated from the nine biomarkers
that were individually highly significantly (P <0.001) asso-
ciated with mortality in univariate analysis. Likewise, the
FI-B-21 was calculated from all 21 significant (P <0.05)
biomarkers and the third group (FI-B-NS-19) from the
remaining 19 biomarkers that individually had shown no
significant association with mortality (P >0.05). In the Cox
regression analysis, each FI-B (comprised from 9, 21, and
19 items) was significantly associated with mortality. The
strongest association was seen with the FI-B-9 (HR, 1.03;
CI, 1.03–1.04) and the FI-B-21 (HR, 1.03; CI, 1.03–1.04)
followed by the FI-B-NS-19 (HR, 1.01; CI, 1.01–1.02).
These relationships did not change after adjustment for
sex and the FI-CD.
Performance of the various frailty measures
The ROC analysis showed moderate discriminative abil-
ity in relation to 7-year mortality for the different frailty
measures (Table 2). The lowest area under the curve
(AUC) value for the FI-B versions was for the FI-B-NS-
19 (AUC = 0.60). The FI-CD had the highest predictive
accuracy, with AUC = 0.71. The AUC further increased
when both the FI-B and FI-CD were entered into the
model (AUC= 0.75), and slightly but insignificantly in-
creased after adjusting for sex (AUC = 0.77). Interestingly,fined by the following cut points: blue <0.25 (low risk, n = 31), red
igh risk, n = 154), pink ≥0.50 (highest risk, n = 32). b Kaplan-Meier
n from the total 40 and stratifying them in four groups with the
Fig. 3 Survival of people who were not clinically frail (FI-CD < lower
quartile) differs by the value of their FI-B: red for those with higher
than median FI-B and blue for those with lower than median FI-B
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discriminative ability: the AUC did not exceed 0.61 (CI,
0.52–0.64; albumin).
Not included in Table 2 is the AUC value obtained for
the Fried frailty phenotype, which was 0.58 (95 % CI,
0.53–0.63), slightly (but not significantly) lower than the
lowest AUC value for the FI-B versions (FI-B-NS-19;
AUC = 0.60). Since the exclusions that were necessary to
produce the data for the Fried frailty phenotype might
have resulted in a generally healthier subsample, which
could potentially have biased the comparison, the ROC
analyses for the various frailty indices were also performed
using only this subsample (Additional file 1: Table S3).
When this was done the predictive accuracy of the various
FIs was reduced but they retained higher AUC values than
for the Fried frailty phenotype. Adding the Fried pheno-
type to FI-CD and FI-B did not change the AUC.
Discussion
Overview of the findings
In this population-based sample of very old people,
combining even ‘small-effect’ biomarkers in a FI resultedTable 2 The area under the receiving operating characteristic
(AUC) with 95 % confidence intervals for different versions of
the frailty index (FI)
AUC 95 % CI
FI-B 0.66 0.62–0.69
FI-B-21 0.68 0.62–0.73
FI-B-9 0.65 0.61–0.69
FI-B-NS 0.60 0.52–0.64
FI-CD 0.71 0.67–0.74
FI-CD + FI-B 0.75 0.71–0.78
FI-CD + FI-B + sex 0.77 0.74–0.81in a strong association with mortality. A FI produced
from 40 biomarkers (and variants of it, based on statistical
criteria) stratified people into four mortality risk groups.
The FI-B was robust to inclusion/exclusion of individual
biomarkers: any 30 randomly selected biomarkers demon-
strated the same patterns of relationship to death. Such
patterns became degraded, with greater overlap between
the neighbouring groups, with decreasing numbers of
biomarkers included (Additional file 1: Figure S2). The
combination of the FI-B and a clinical FI, FI-CD, sig-
nificantly improved mortality prediction compared to
either index alone.
Comparing the FI-B and FI-CD
Although the FI-B and FI-CD were significantly but
weakly correlated, they showed different distributions.
On average, the clinically fittest people (those with 0 or
1 clinical deficits, i.e., FI-CD, 0 or 0.02) had an average
FI-B value of 0.33 (CI, 0.32–0.34). The 95th and 99th
centiles for both frailty indices were very similar (0.46 for
FI-CD and 0.48 for FI-B for the former; 0.59 for FI-CD
and 0.60 for the latter), whereas the 5th centiles were dif-
ferent (0.06 for FI-CD vs. 0.24 for FI-B). This suggests
that, at low FI-CD values, the FI-B is a more sensitive
measure of health, i.e., it indicates important subclinical
deficit accumulation (Fig. 3) whereas the frailest group is
frail by either measure. The observation that FI-B is a
stronger predictor of mortality in the group who were not
clinically frail points to a question: do people with low
FI-CD and high FI-B become clinically frail before death?
To answer this will require follow-up data on the people
who were non-frail in an earlier phase of assessment. Even
so, the FI-B was not as closely associated with mortality as
was the FI-CD, suggesting that the added value of bio-
markers is highest in people without detectable clinical
deficits. Note too that in both distributions, the right tail
shows that 99.5 % of people had an FI value <0.7 in either
the FI-B or the FI-CD. The reproducibility of this observa-
tion [7, 25–28] is consistent with a system property that
has yet to be elucidated.
Combining the FIs
Combining the FI-B and FI-CD resulted in an increase
in their discriminative ability (AUC = 0.76; compared to
0.68 for FI-B and 0.71 for FI-CD, separately). This indi-
cates that the indices are complementary to each other.
At this age, the clinically fittest people as measured by
the FI-CD, still have an important number of biomarker
abnormalities, as reflected by their high mean FI-B scores
of 0.32, well above the usual levels in a FI-CD of 0.20–0.25
that would define a person as “frail” using a dichotomous
definition. Even so, changes that are subclinical alone ap-
pear to be less related to mortality; to what extent they
predict adverse outcomes other than mortality will be of
Mitnitski et al. BMC Medicine  (2015) 13:161 Page 7 of 9interest. Interestingly, the AUC for the combination of
FI-CD with the FI-B-NS-19 and adjusted for sex was
0.75, suggesting further that the additive effect of items
is important, even for those that individually might not
be statistically significant.
IL-6 and TNFα data
It was interesting that neither basal nor stimulated non-
coagulated cytokine production were associated with
7-year survival. This is in accordance with our earlier report
of absence of an association between these inflammatory
markers and 18-month survival [24], although basal IL-6
was earlier associated with frailty (both Fried frailty and the
FI-CD) [15]. We are aware that serum IL-6 and TNFα
levels have been associated with survival in other studies.
There are a number of speculations possible regarding the
comparative predictive power of cell-based versus serum-
based measures, but we believe these would be premature
at this stage.
Strengths and limitations
Our data must be interpreted with caution. Often, ab-
normalities are expressed only in one direction (i.e., only
values above (or below) a reference level are considered
‘abnormal’) [15]. Our approach was strictly empirical: for
each dichotomized biomarker variable, we tested whether
the highest or lowest scores were associated with mortal-
ity. The potential for increased risk at both ends of the
normal range has been observed for several characteristics
[29–31]. Even so, we did not find evidence of a U-shaped
risk of mortality for any of these biomarkers (Table 1).
Here, whichever direction was associated with increased
mortality was scored as a deficit for that item (Table 1 and
Additional file 1: Figure S1), as has been done for all
versions of the FI. This method of identifying cut-points is
likely to be related to mortality within studies, so that it is
not clear how generalizable it is to other populations. This
needs to be evaluated. On the other hand, percentile-
based cut-points, e.g., tertiles [32] or twentieth percentile
rule [33], also depend on the population sample consid-
ered in those studies. Often, such cut-points are not well
established, so that we were interested to note that our
algorithm-identified cut-point for telomere length was
virtually identical to what others have suggested [34–36].
The fact that we used mortality data to establish cut-
points in order to dichotomise the biomarker values,
and later used the resulting aggregate FIs to predict
mortality, could also be considered a limitation. However,
this was necessary given the lack of independent data, and
any distortion is likely to have been small. As future data
accrue, it should become possible for cut-point determin-
ation to be done on one population and prediction on an-
other. Participants were all over the age of 85 years, which
can limit generalizability. On the other hand, there is a highprevalence of clinical frailty in this under-investigated
group. Furthermore, at this age, for a modest sample size –
and budget – many events are likely to accrue.
Our study has several strengths. An important aspect
of this study is the population-based nature of the sam-
ple [15]. In addition to the sample size and the range of
biomarkers considered, it is the first study in which the
FI approach has been applied to biomarkers. The FI-B
shared many properties with the FI-CD, although it adds
important value to the latter in identifying people at in-
creased risk of death. The availability of a large number
of biomarkers in this study allowed us to make a direct
comparison of the different frailty measures, and also to
assess the robustness of the FI-B to its composition of
individual biomarkers. We have indicated how the algo-
rithm for biomarker cut-points can be defined, which,
coupled with earlier publications [9, 37, 38] on a stand-
ard procedure for creating a FI, allows for replication of
the results by others.
Frailty and ageing: conceptualisation
Although, as generally agreed, frailty is an age-related
state of vulnerability to stressors, there are different ways to
operationalize it. Frailty as defined by a clinical phenotype
exposes the consequences of functional deterioration and
indicates proximate factors that render the frail individual
more likely to die. By contrast, if frailty can be related to
biological markers of aging, these relationships should
come closer to identifying the underlying factors that
give rise to these functional declines. Within the frailty
phenotype approach, the focus has been on clinical fea-
tures of frailty; while it has been acknowledged that these
need ultimately to be understood in terms of biological
mechanisms, the connection has not yet been established.
On the other hand, the FI approach has been chiefly one
based on pragmatic scoring of multiple clinical deficits, to
which subclinical ones can be added [39]. Thus, its poten-
tial utility is that the FI-B could be used as a pre-clinical
measure to identify at-risk individuals before changes
are apparent on clinical examination. The FI-B might also
help to inform the mechanistic connections between frailty
and the underlying biology of intrinsic aging. This frame-
work also allows a practical means of addressing a funda-
mental fact of old age, which is, as pointed out in a recent
Nature commentary [40], that its problems come as a
package.
Conclusions
Combining biomarkers in a FI, even those not individually
associated with mortality, improves mortality prediction
much beyond that of individual biomarkers. Additionally,
combining a FI based on biomarkers with one based on
clinically detectable deficits further improves the perform-
ance in identifying vulnerable people who are at risk of
Mitnitski et al. BMC Medicine  (2015) 13:161 Page 8 of 9death. Finally, that so many items can contribute to mor-
tality prediction reflects the systemic nature of ageing and
mortality – health status depends on the systemic effect of
multiple characteristics, of which those located within the
individual can be summarized in a FI.
Additional file
Additional file 1: Figure S1. Kaplan-Meier survival curves of the individual
biomarkers split by two groups using the cut points chosen to achieve
the best separation of survival curves between people with and without the
deficit and minimizing the p-value of the log rank test (Table 1). Red lines
show survival curves for the group “at higher risk” and the blue lines are for
“at lower risk” individuals.
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